JP2018507860A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507860A5
JP2018507860A5 JP2017544759A JP2017544759A JP2018507860A5 JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5 JP 2017544759 A JP2017544759 A JP 2017544759A JP 2017544759 A JP2017544759 A JP 2017544759A JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5
Authority
JP
Japan
Prior art keywords
amino acid
binding domain
seq
protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017544759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507860A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019401 external-priority patent/WO2016138164A1/en
Publication of JP2018507860A publication Critical patent/JP2018507860A/ja
Publication of JP2018507860A5 publication Critical patent/JP2018507860A5/ja
Pending legal-status Critical Current

Links

JP2017544759A 2015-02-26 2016-02-24 抗原特異的t細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物 Pending JP2018507860A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121406P 2015-02-26 2015-02-26
US62/121,406 2015-02-26
PCT/US2016/019401 WO2016138164A1 (en) 2015-02-26 2016-02-24 A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses

Publications (2)

Publication Number Publication Date
JP2018507860A JP2018507860A (ja) 2018-03-22
JP2018507860A5 true JP2018507860A5 (enExample) 2018-12-20

Family

ID=56789742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017544759A Pending JP2018507860A (ja) 2015-02-26 2016-02-24 抗原特異的t細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物

Country Status (10)

Country Link
US (1) US9775898B2 (enExample)
EP (1) EP3261667A4 (enExample)
JP (1) JP2018507860A (enExample)
KR (1) KR20170105107A (enExample)
CN (1) CN107249629A (enExample)
BR (1) BR112017018017A2 (enExample)
IL (1) IL254110A0 (enExample)
RU (1) RU2017129818A (enExample)
TW (1) TWI674269B (enExample)
WO (1) WO2016138164A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531292A (ja) * 2016-09-19 2019-10-31 ザヴァックス ジェネティクス ワクチン カンパニー リミテッドThevax Genetics Vaccine Co., Ltd. B型肝炎治療ワクチン
WO2019133647A1 (en) * 2017-12-29 2019-07-04 Thevax Genetics Vaccine Co., Ltd. Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses
CN109134667A (zh) * 2018-09-19 2019-01-04 天康生物股份有限公司 融合蛋白及其制备方法、应用、表达系统和疫苗
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔(苏州)生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
TWI763065B (zh) * 2019-10-04 2022-05-01 瑞寶基因股份有限公司 重組融合蛋白及免疫原組合物
US20230040021A1 (en) * 2019-12-13 2023-02-09 Grand Theravac Life Science (Nanjing) Co., Ltd. Immunostimulatory composition and use thereof
EP4146701A4 (en) * 2020-05-06 2024-05-15 Navicure Biopharmaceuticals Limited Fusion proteins for immunotherapy against cancer and infectious diseases
CN111548395A (zh) * 2020-05-25 2020-08-18 中国农业科学院兰州兽医研究所 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用
CN112626073B (zh) * 2020-10-26 2021-06-15 中国科学院昆明动物研究所 一种对PRRSV具有特异性免疫刺激作用的CpG-ODN及其应用
EP4442272A4 (en) * 2021-12-28 2025-07-02 Chengdu Maxvax Biotechnology LLC VACCINE ADJUVANT, ITS PREPARATION PROCESS AND ITS USE
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156710T1 (de) * 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
AU773204C (en) * 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
RU2005124130A (ru) * 2003-01-29 2006-01-20 Пфайзер Продактс Инк. (Us) Вакцины для собак против bordetella bronchiseptica
AU2004208850A1 (en) 2003-02-04 2004-08-19 University Of Connecticut Health Center Immunogenic CD91 ligand-antigenic molecule complexes and fusion proteins
AU2003272065A1 (en) * 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
KR20090071598A (ko) * 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(rap)-접합체 투여에 의한 간 질환의 치료
EP2078726A1 (en) * 2008-01-09 2009-07-15 Vision 7 GmbH Secretable HIV entry inhibitory peptides for therapy of HIV infection
WO2009099777A2 (en) * 2008-01-31 2009-08-13 Healthbanks Usa Inc. Chimeric hiv fusion proteins as vaccines
KR20110050531A (ko) 2008-08-28 2011-05-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
EP2575868A1 (en) * 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
DK2609931T3 (da) * 2010-08-26 2020-12-07 Toray Industries Immunogen sammensætning
US9481714B2 (en) * 2012-12-05 2016-11-01 Thevax Genetics Vaccine Co., Ltd. Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
AU2014284457A1 (en) 2013-07-03 2016-01-28 Visterra, Inc. Synthetic oligosaccharides for P. aeruginosa vaccine
US20150037374A1 (en) * 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
JP2019531292A (ja) * 2016-09-19 2019-10-31 ザヴァックス ジェネティクス ワクチン カンパニー リミテッドThevax Genetics Vaccine Co., Ltd. B型肝炎治療ワクチン

Similar Documents

Publication Publication Date Title
JP2018507860A5 (enExample)
RU2017129818A (ru) Композиция вакцины, содержащая иммуногенный белок и комбинированные адъюванты, для применения в стимулировании антигенспецифичных т-клеточных ответов
EP2928491B1 (en) Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
JP2016199557A5 (enExample)
JP2016510983A5 (enExample)
JP2015509707A5 (enExample)
JP2014530003A5 (enExample)
JP2016519658A5 (enExample)
JP2013526849A5 (enExample)
JP2015212284A5 (enExample)
JP2021502807A5 (enExample)
ES2790527T3 (es) Composiciones de vacunas contra el síndrome reproductivo y respiratorio porcino y las enfermedades asociadas al circovirus porcino
IL274130B1 (en) HIV–1 vaccine immunogens with novel scaffolds
JP2016520534A5 (enExample)
JP2020534874A5 (enExample)
JP2018501258A5 (enExample)
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
Shen et al. Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact
RU2007147938A (ru) Конъюгаты антигенов и их применение
ES3030310T1 (en) Sars-cov-2 subunit vaccine
WO2010088393A3 (en) Li-kay hybrid peptides that modulate the immune response to influenza
CU24751B1 (es) Antígeno recombinante para la inducción de respuesta inmune contra el virus zika
TH114418A (th) วัคซีน